First test of new cancer drug mix for Tough-to-Treat tumors
NCT ID NCT01352962
Summary
This early-stage study aimed to find the safest and most effective dose of a three-drug combination (gemcitabine, carboplatin, and lenalidomide) for people with advanced solid tumors, especially bladder cancer, that had not responded to standard treatments. It involved 18 adults and was the first to test this specific combination. The main goal was to understand the side effects and determine the best dose for future research, not to cure the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URETHRAL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.